|Bid||0.8830 x 900|
|Ask||0.8860 x 1100|
|Day's Range||0.8340 - 0.9369|
|52 Week Range||0.8000 - 2.8700|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.75|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, is providing an update on the company’s corporate strategy and outlook following the recent termination of its proposed merger with BioCryst Pharmaceuticals. Vincent Milano, Idera’s Chief Executive Officer stated, “Today, we advance the next chapter of our company’s future with a clear picture of our mission, which is to ultimately deliver tilsotolimod to as many patients suffering from cancer as we possibly can.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Idera shareholders voted in favor of the deal. The Chester County company will get $6M as a result of the termination.
The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...
There will be no deal as shareholders of Research Triangle Park-based BioCryst Pharmaceuticals have blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals.
Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.
MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.
Idera Pharmaceuticals, Inc. (IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated. The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioCryst’s stockholders voted against the proposed mergers. Separately, a majority of Idera’s stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Idera stockholders, also held on July 10, 2018.
On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).
13Ds are filed with the Securities and Exchange Commission within 10 days of an entity’s attaining a greater than 5% position in any class of a company’s securities. Source: InsiderScore.com On June 14, Kimmeridge Energy Management disclosed its stake of 1,582,052 shares of the oil-and-gas producer, equal to 6.8% of the outstanding stock, following the purchase of 480,752 shares at prices ranging from $29.14 to $29.89 apiece from May 8 through June 6. Also on June 14, Kimmeridge revealed that it supports Resolute’s agreement with fellow investor Monarch Alternative Capital’s assessment that the company needs to consider “potential strategic alternatives.” Kimmeridge said that it has “consistently expressed” to management that Resolute is “subscale” and that it should focus on “alternative strategies, including a potential merger with a “similarly positioned” peer or the outright sale of the company.
GREENWICH, Conn. , June 20, 2018 /PRNewswire/ -- Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing ...
LONDON, UK / ACCESSWIRE / June 14, 2018 / If you want access to our free research report on Idera Pharma, Inc. (NASDAQ: IDRA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IDRA as the Company's latest news hit the wire. On June 12, 2018, the Cambridge-based Company announced that the Phase-2 clinical trial assessing IMO-8400 in adult patients with dermatomyositis did not meet its primary endpoint.
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced that they will be presenting at the JMP Securities Life Sciences ...
Idera Pharmaceuticals Inc.'s stock plummeted 19% in premarket trade Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment for dermatomyositis (IMO-8400) failed to meet its primary endpoint. The company, which develops toll-like receptors and RNA therapeutics for patients with rare cancers and diseases, said the primary endpoint was for statistically significant change from baseline versus placebo.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced topline results from the Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered Toll-like Receptor (TLR) 9 agonist, in combination with ipilimumab (Yervoy®*). Current data show an overall response rate (ORR) of 38 percent following treatment with the combination of tilsotolimod and ipilimumab. This includes 2 complete responses (1 ongoing for 23 months) and an ongoing PR for 12 months. “We have clinical evidence that tilsotolimod activates both the innate and adaptive immune responses, and when used in combination with a checkpoint inhibitor like ipilimumab, triggers immune responses in previously resistant tumors,” stated Adi Diab, M.D., Lead Trial Investigator, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., May 24, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced that they will be presenting at the Jefferies 2018 Global Healthcare ...